论文部分内容阅读
1例74岁男性冠状动脉粥样硬化性心脏病患者于冠状动脉支架植入术后应用硫酸氢氯吡格雷、阿司匹林、通心络、辅酶Q_(10)、阿托伐他汀钙、维生素E及维生素C。因降脂效果不达标,患者自行停用阿托伐他汀钙,改服瑞舒伐他汀钙10 mg,1次/d。随后4个月,患者血糖水平较前升高,空腹血糖波动于6.5~7.8 mmol/L,餐后血糖波动于7.7~10.5 mmol/L。7个月后,患者空腹血糖达12.5 mmol/L,餐后血糖达16.0 mmol/L,糖化血红蛋白9.6%。患者自行停用瑞舒伐他汀钙。3个月后,空腹血糖降至5.9 mmol/L,餐后血糖降至7.4 mmol/L,糖化血红蛋白降至6.6%。
A 74-year-old man with coronary atherosclerotic heart disease after coronary stenting was treated with clopidogrel hydrogen sulfate, aspirin, Tongxinluo, coenzyme Q_ (10), atorvastatin calcium, vitamin E and Vitamin C. Due to lipid-lowering effect of non-compliance, patients stop using atorvastatin calcium, change service rosuvastatin calcium 10 mg, 1 time / d. The subsequent 4 months, the patient’s blood glucose levels increased compared with the previous, fasting blood glucose fluctuations in 6.5 ~ 7.8 mmol / L, postprandial blood glucose fluctuations in 7.7 ~ 10.5 mmol / L. After 7 months, the fasting blood glucose reached 12.5 mmol / L, the postprandial blood glucose reached 16.0 mmol / L, and the glycosylated hemoglobin was 9.6%. Patients discontinue rosuvastatin calcium on their own. After 3 months, the fasting blood glucose dropped to 5.9 mmol / L, postprandial blood glucose dropped to 7.4 mmol / L and HbA1c to 6.6%.